METHODS OF USING ACTIVIN RECEPTOR TYPE II VARIANTS

Abstract

The invention features methods for the treatment of Alport syndrome using a polypeptide containing an extracellular ActRII variant, such as a polypeptide containing an extracellular ActRII chimera or an extracellular ActRIIB variant. The polypeptide may include an extracellular ActRII chimera or an extracellular ActRIIB variant fused to an Fc domain monomer. Treatment of Alport syndrome with a polypeptide described herein may reduce kidney inflammation, reduce kidney fibrosis, slow disease progression, and/or improve kidney function, which may reduce or delay the need for a kidney transplant or dialysis.

CPC Classifications